Clinical trial
A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
NCT03037385 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- March 17, 2017
- Completion date
- March 21, 2024
- Enrollment
- 590 (actual)
- Sites
- 71
Conditions
As the registry lists them; a condition with its own page is linked.
adenocarcinoma, adenocarcinoma, papillary, bronchial neoplasms, carcinoma, carcinoma, bronchogenic, carcinoma, neuroendocrine, carcinoma, non-small-cell lung, colonic diseases, colonic neoplasms, colorectal neoplasms, digestive system disease, digestive system neoplasm, endocrine gland neoplasm, endocrine system diseases, gastrointestinal disease, gastrointestinal neoplasms, head and neck neoplasms, intestinal disease, intestinal neoplasms, lung diseases, lung neoplasm, medullary thyroid cancer, neoplasms, neoplasms by histologic type, neoplasms by site, neoplasms, germ cell and embryonal, neoplasms, glandular and epithelial, neoplasms, nerve tissue, neuroectodermal tumors, neuroendocrine tumors, respiratory tract disease, respiratory tract neoplasms, ret-altered colon cancer, ret-altered non small cell lung cancer, ret-altered papillary thyroid cancer, ret-altered solid tumors, thoracic neoplasms, thyroid cancer, papillary, thyroid diseases, thyroid neoplasm